Pyoderma gangrenosum
Pyoderma gangrenosum ialah penyakit kulit radang yang jarang berlaku di mana pustula atau nodul yang menyakitkan menjadi ulser yang tumbuh secara beransur-ansur. Pyoderma gangrenosum tidak berjangkit. Rawatan mungkin termasuk kortikosteroid, cyclosporin, atau pelbagai antibodi monoklonal. Walaupun ia boleh menjejaskan orang dari sebarang umur, ia kebanyakannya memberi kesan kepada orang yang berumur 40-an dan 50-an.
☆ Dalam keputusan Stiftung Warentest 2022 dari Jerman, kepuasan pengguna terhadap ModelDerm hanya lebih rendah sedikit berbanding dengan perundingan teleperubatan berbayar.
Pada kaki seseorang yang menghidap kolitis ulseratif.
References
Pyoderma gangrenosum ialah keadaan kulit yang jarang berlaku yang menyebabkan ulser yang menyakitkan dengan tepi merah atau keunguan. Ia diklasifikasikan sebagai penyakit radang dan merupakan sebahagian daripada kumpulan yang dipanggil dermatosis neutrophilic. Punca pyoderma gangrenosum adalah kompleks, melibatkan masalah dengan imuniti semula jadi dan adaptif pada orang yang terdedah secara genetik. Baru-baru ini, para penyelidik telah memberi tumpuan kepada folikel rambut sebagai titik permulaan yang berpotensi untuk penyakit ini.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum adalah keadaan kulit yang jarang berlaku menyebabkan ulser yang sangat menyakitkan. Walaupun kami tidak memahami sepenuhnya puncanya, kami tahu ia melibatkan peningkatan aktiviti sel imun tertentu. Mengubati penyakit ini masih tidak mudah. Kami mempunyai pelbagai ubat yang menekan sistem imun atau mengubah suai aktivitinya. Di samping itu, kami juga memberi tumpuan kepada merawat luka dan menguruskan kesakitan. Kortikosteroid dan siklosporin selalunya merupakan pilihan pertama untuk rawatan, tetapi sejak kebelakangan ini, terdapat lebih banyak kajian tentang menggunakan terapi biologi seperti perencat TNF-α. Biologik ini semakin diutamakan, terutamanya pada pesakit dengan keadaan keradangan lain, dan ia digunakan lebih awal dalam proses penyakit.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
